Market Performance - The Shanghai Composite Index rose by 1.38% to 4023.42 points, while the Shenzhen Component increased by 2.24% and the ChiNext Index surged by 2.85%[1] - The Hang Seng Index in Hong Kong slightly increased by 0.03% to 26347.24 points, with the Hang Seng Tech Index up by 0.09% and the Hang Seng China Enterprises Index down by 0.22%[1] - The total trading volume in the Hong Kong market reached 2834.623 million HKD[1] Economic Indicators - The US ISM Manufacturing Index fell to a one-year low of 47.9, indicating continued contraction in factory activity, marking the tenth consecutive month below the neutral level of 50[11] - New orders in the US manufacturing sector have contracted for the fourth consecutive month, with employment indicators remaining below the growth threshold for eleven months[11] International Developments - China has requested banks to report their loan exposure risks related to Venezuela, emphasizing the need for enhanced risk monitoring of all credit related to Venezuela[11] - The Swiss government has frozen assets belonging to Venezuelan President Nicolás Maduro and his associates for a provisional period of four years[11] Sector Highlights - The AI pharmaceutical and brain-computer interface sectors saw significant gains, reflecting strong investor interest in technology-driven healthcare solutions[1] - The insurance, medical, and semiconductor sectors also showed robust performance in the market[1]

本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 承董事局命 執行董事兼公司秘書 周興揚 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 自願公告 產品開發的最新進展 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團已取得中國國家藥品監督管理局有關培哚普利氨氯地平片（Ⅲ）（精氨酸培哚普利10mg、 苯磺酸氨氯地平5mg）的藥品生產註冊批件，屬於化學藥品第4類，視同通過一致性評價。 培哚普利氨氯地平片（Ⅲ）是複方製劑，主要用於單藥治療不能充分控制高血壓的成人患者， 或作為替代療法用於在相同劑量水平的培哚普利和氨氯地平聯合治療下病情得以控制的原發 性高血壓。 香港，二零二六年一月五日 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 ...

苑东生物(688513.SH)公告称，全资子公司硕德药业于近日收到国家药监局核准签发的《药品注册证 书》，药品名称为培哚普利氨氯地平片（Ⅲ）。该药品为复方制剂，主要用于治疗 高血压。培哚普利 氨氯地平片（Ⅲ）由法国施维雅开发，最早于2008年3月在欧盟获批上市。硕德药业该药品获批后视同 通过一致性评价。根据米内网数据，2024年该药品销售金额约4.36亿元。 ...

Group 1: Company Performance - Jinli Permanent Magnet expects a net profit of 300 million to 335 million yuan for the first half of 2025, representing a year-on-year increase of 151% to 180% [2] - Zhongji Xuchuang anticipates a net profit of 3.6 billion to 4.4 billion yuan for the first half of 2025, reflecting a growth of 52.64% to 86.57% compared to the previous year [4] - China Galaxy forecasts a net profit of 6.362 billion to 6.801 billion yuan for the first half of 2025, indicating a year-on-year increase of 45% to 55% [5] - Meili Technology projects a net profit increase of 66.85% to 92.52% for the first half of 2025 [8] - Blue Ocean Huaten expects a net profit growth of 152.76% to 190.68% for the first half of 2025 [7] Group 2: Shareholder Actions - China Life intends to reduce its stake in Hangzhou Bank by no more than 0.7%, equating to approximately 50.79 million shares [2] - Zhongsheng High-Tech is planning a transfer of 22.35% of its shares, potentially leading to a change in control, with a transaction value of 2.5 billion yuan [3] - Fangzheng Technology's major shareholder plans to reduce its stake by no more than 2.27% [10] Group 3: Investment Activities - Bertley plans to invest 198 million yuan in a partnership focused on high-growth unlisted companies in humanoid robotics and automotive intelligence [3] - Rock Mountain Technology's subsidiary is participating in an investment fund targeting Bytedance Ltd, with a commitment of 20.32 million yuan [6] - Zhonghua International is planning to acquire 100% of Nantong Xingchen's equity, leading to a temporary suspension of its stock [2]